Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/117029
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Weiss, Michael | - |
dc.contributor.author | D'Argenio, David Z. | - |
dc.contributor.author | Siegmund, Werner | - |
dc.date.accessioned | 2024-11-06T06:30:03Z | - |
dc.date.available | 2024-11-06T06:30:03Z | - |
dc.date.issued | 2022 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/118989 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/117029 | - |
dc.description.abstract | Purpose: In order to clarify the effect of rifampicin on the bioavailability of the P-glycoprotein substrate talinolol, its absorption kinetics was modeled after multiple-dose oral administration of talinolol in healthy subjects. Methods: A sum of two inverse Gaussian functions was used to calculate the time course of the input rate into the systemic circulation. Results: The estimated rate of drug entry into the systemic circulation revealed two distinct peaks at 1 and 3.5 h after administration. Rifampicin did not affect bioavailability of talinolol, but did shift the second peak of the input function by 1.3 h to later times. Elimination clearance and one of the intercompartmental distribution clearances increased significantly under rifampicin treatment. Conclusions: Rifampicin changes the time course of absorption rate but not the fraction absorbed of talinolol. The model suggests the existence of two intestinal absorption windows for talinolol. | eng |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject.ddc | 615 | - |
dc.title | Analysis of complex absorption after multiple dosing : application to the interaction between the P-glycoprotein substrate talinolol and rifampicin | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Pharmaceutical research | - |
local.bibliographicCitation.volume | 39 | - |
local.bibliographicCitation.issue | 12 | - |
local.bibliographicCitation.pagestart | 3293 | - |
local.bibliographicCitation.pageend | 3300 | - |
local.bibliographicCitation.publishername | Springer Science + Business Media B.V | - |
local.bibliographicCitation.publisherplace | Dordrecht [u.a.] | - |
local.bibliographicCitation.doi | 10.1007/s11095-022-03397-6 | - |
local.subject.keywords | absorption kinetics, interaction, multiple dosing, rifampicin, talinolol | - |
local.openaccess | true | - |
dc.identifier.ppn | 1843055228 | - |
cbs.publication.displayform | 2022 | - |
local.bibliographicCitation.year | 2022 | - |
cbs.sru.importDate | 2024-11-06T06:29:27Z | - |
local.bibliographicCitation | Enthalten in Pharmaceutical research - Dordrecht [u.a.] : Springer Science + Business Media B.V, 1984 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s11095-022-03397-6.pdf | 999.32 kB | Adobe PDF | View/Open |